Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Study could point the way to new treatments for people with severe asthma

The immune response that occurs in patients with severe asthma is markedly different than what occurs in milder forms of the lung condition, according to researchers from the University of Pittsburgh School of Medicine. Those unique features could point the way to new treatments, they said in an article published online today in the Journal of Clinical Investigation.

30 Jun 2015

Veracyte named to Bay Area News Group's Top Workplaces list for second consecutive year

Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has been named to the Bay Area News Group's prestigious Top Workplaces list for the second year in a row. The news group selects Top Workplace winners based solely on an annual survey of Bay Area-company employees.

29 Jun 2015

Spyryx receives award from Cystic Fibrosis Foundation to development therapeutic peptides for CF

Spyryx Biosciences, Inc., a privately-held biopharmaceutical company developing novel therapeutics for obstructive lung diseases, announced today it has received an award from Cystic Fibrosis Foundation Therapeutics, which will support development of Spyryx' therapeutic peptides for cystic fibrosis (CF).

26 Jun 2015

Animal study highlights major safety concern regarding use of MRI contrast agents in patients

New results in animals highlight a major safety concern regarding a class of magnetic resonance imaging (MRI) contrast agents used in millions of patients each year, according to a paper published online by the journal Investigative Radiology.

26 Jun 2015

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Cell transplantation researchers have successfully used bone marrow-derived mesenchymal stromal cells (MSCs) to treat a variety of diseases and conditions. Now, using injections of MSCs, a research team in Brazil has successfully treated laboratory rats modeled with severe burns.

25 Jun 2015

Study shows cystic fibrosis is more deadly for Hispanic than non-Hispanic patients

Cystic fibrosis is more deadly for Hispanic than non-Hispanic patients, a disparity that is not explained by differences in their access to health care, according to a new study from the Stanford University School of Medicine.

25 Jun 2015

Annual LDCT screening safe, effective for monitoring patients with nonsolid lung nodules

An annual exam using a key imaging technology could spare patients with lung nodules from unnecessary tests and surgery, while identifying the cases where the nodules are likely to become cancerous, according to a new study by researchers at Icahn School of Medicine at Mount Sinai (ISMMS) and published online today in journal Radiology.

24 Jun 2015

Low-dose CT screening can help monitor people who have nonsolid lung nodules

People who have nonsolid lung nodules can be safely monitored with annual low-dose computed tomography (CT) screening, according to a new study published online in the journal Radiology. Researchers said the findings could help spare patients from unnecessary surgery and additional imaging.

23 Jun 2015

New research sheds light on molecular architecture of receptors linked to many brain diseases

Scientists at The Scripps Research Institute have teamed up with several other institutions and pharmaceutical companies, including the University of Southern California (USC), San Diego's Receptos Inc. and Japanese company Ono Pharmaceutical Co., Ltd., to publish the first 3D structures of a receptor implicated in many diseases of the brain and in normal physiology throughout the body.

22 Jun 2015

$Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC$

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.

19 Jun 2015

Autoantibodies play major role in IPF patients with acute exacerbations

Patients with acute exacerbations of idiopathic pulmonary fibrosis responded well to therapies similar to those used to treat autoimmune diseases, according to findings published today in PLOS ONE. The study suggests that autoantibodies — implicated in many autoimmune diseases such as rheumatoid arthritis or lupus — also play an important role in patients with acute exacerbations of IPF, a devastating lung disease.

18 Jun 2015

UW microbiologist receives 2015 Shaw Prize in life science and medicine

UW microbiologist Peter Greenberg has long been fascinated with how bacteria in cells communicate for cooperative activities, including the spread of infection. He started exploring the subject in 1977, thinking the implications could be far-reaching.

18 Jun 2015

Loyola patient celebrates 10th anniversary of heart and double-lung transplant

On March 20, Andrew Gaumer celebrated the 10th anniversary of his life-saving heart and double-lung transplant. On Mother's Day, his wife, Andrea, gave birth to their first child, a baby boy named Jude. And on June 21, Andrew will celebrate his first Father's Day - a milestone he once feared he would never see.

17 Jun 2015

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).

16 Jun 2015

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.

16 Jun 2015

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V., one of the world's leading global pharmaceutical companies.

16 Jun 2015

Laurent reports positive topline results from LAU-7b Phase 1b trial in adult CF patients

Laurent Pharmaceuticals Inc. announced today positive topline results from a Phase 1b clinical trial with LAU-7b in adult CF patients. LAU-7b is a novel oral formulation of fenretinide, a synthetic retinoid investigated for its lipid modulating properties and potential to address the aberrant inflammatory response in CF.

15 Jun 2015

Study shows bacteriophages remain active against P. aeruginosa infection after nebulization

bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. aeruginosa) after nebulization.

15 Jun 2015

Triciribine drug may reverse progression of pulmonary fibrosis and pulmonary hypertension

Researchers at the University of Georgia have discovered that the drug triciribine may reverse or halt the progression of pulmonary fibrosis and pulmonary hypertension, two respiratory diseases that are almost invariably fatal.

13 Jun 2015

Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

A Montréal research team, co-supervised by Dr. Rémi Rabasa-Lhoret from the IRCM and Dr. Laurent Legault from the Montreal Children's Hospital, undertook the first paediatric outpatient study to compare three alternative treatments for type 1 diabetes.

11 Jun 2015

Fibrosis News and Research

Further Reading

Study could point the way to new treatments for people with severe asthma

Veracyte named to Bay Area News Group's Top Workplaces list for second consecutive year

Spyryx receives award from Cystic Fibrosis Foundation to development therapeutic peptides for CF

Animal study highlights major safety concern regarding use of MRI contrast agents in patients

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Study shows cystic fibrosis is more deadly for Hispanic than non-Hispanic patients

Annual LDCT screening safe, effective for monitoring patients with nonsolid lung nodules

Low-dose CT screening can help monitor people who have nonsolid lung nodules

New research sheds light on molecular architecture of receptors linked to many brain diseases

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Autoantibodies play major role in IPF patients with acute exacerbations

UW microbiologist receives 2015 Shaw Prize in life science and medicine

Loyola patient celebrates 10th anniversary of heart and double-lung transplant

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Laurent reports positive topline results from LAU-7b Phase 1b trial in adult CF patients

Study shows bacteriophages remain active against P. aeruginosa infection after nebulization

Triciribine drug may reverse progression of pulmonary fibrosis and pulmonary hypertension

Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News